Close menu



  • OREGA Biotech grants Genmab rights to its first-in-class antibody against a novel, undisclosed immuno-oncology target
  • Under the License Agreement with OREGA Biotech, Genmab will obtain the exclusive, worldwide right to develop and commercialize novel antibody therapeutics utilizing OREGA Biotech’s first-in-class antibody  
  • OREGA Biotech to receive an upfront payment and is eligible to receive development, regulatory and commercial milestone payments along with royalties on commercial sales. 



Read the press release